On June 1, 2026 NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, reported the appointment of Ian Webster as Chief Financial Officer, effective today. Ian has served as Interim Chief Financial Officer since June 2025 and was previously Director of Finance since joining NuCana in 2019.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are delighted to appoint Ian as Chief Financial Officer," said Hugh S. Griffith, Founder and Chief Executive Officer of NuCana. "Since joining NuCana, Ian has demonstrated deep financial expertise and a thorough understanding of our business. He will continue to shape our financial strategy as we advance our pipeline, including our plans to generate data in 2026 from the Phase 2 NuTide:701 study evaluating NUC-7738 in combination with Keytruda (pembrolizumab) in patients with PD-1 inhibitor-resistant metastatic melanoma and to prepare the optimal pathway toward a potential registrational strategy for NUC-7738 in melanoma."
"I am honored to be appointed Chief Financial Officer at such an exciting time for NuCana," said Ian Webster. "With multiple anticipated data readouts and a cash runway anticipated to extend into 2029, I look forward to helping advance the Company’s strategic priorities and long-term value creation."
Ian brings more than 20 years of finance experience to the Chief Financial Officer role, including over a decade in senior leadership positions within the biopharmaceutical sector. His expertise spans financial management, public company reporting, audit, tax, mergers and acquisitions, as well as financial planning and analysis.
Prior to joining NuCana, Ian served as Group Financial Controller at Kyowa Kirin International plc, a specialty pharmaceutical company, from 2013 to 2019. Earlier in his career, he spent 11 years at PricewaterhouseCoopers LLP, where he was a senior manager in the audit and transaction services practices in the United Kingdom and Canada.
Ian is a chartered accountant with the Institute of Chartered Accountants of Scotland and holds a BSc Honours in Accounting and Finance from the University of Warwick.
(Press release, Nucana, JUN 1, 2026, View Source [SID1234666315])